Company intelligence / Profile preview

BioElectronics Corporation

Frederick, Maryland, USAbielcorp.com ↗

Ownership: Private
Development stage: Commercial

Overview

BioElectronics has received FDA market clearance for its non-opioid postoperative pain therapy. The company has filed FDA 510(k) applications for musculoskeletal pain complaints, with clinical data demonstrating superior drug-free pain relief compared to prescription-strength NSAID drugs.

Therapeutic areas: Women's HealthDermatologyNeurologyRheumatology
Modalities: Non-invasive electroceutical medical devices
Industry: Therapeutic Medical Devices

Drug pipeline

2 assets

ActiPatch

Commercial

Indications: Musculoskeletal pain, Chronic pain

1 more asset in the full pipeline.

Request access →

Partnerships

PRIM Group (Spain)

Beyond the preview

Go deeper on BioElectronics Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioElectronics Corporation.

Explore the full profile